Compare Lamb Weston Holdings Inc (LW) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lamb Weston Holdings Inc vs Revvity Inc — how do they compare? Lamb Weston Holdings Inc trades at $47.77 (market cap $6.81B), while Revvity Inc trades at $154.1 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 2.5× Lamb Weston Holdings Inc's market cap, and Lamb Weston Holdings Inc pays the higher dividend (3.07%). Which is the better fit depends on your goals — on Pluang, investors hold Lamb Weston Holdings Inc for 66 Days and Revvity Inc for 12 Days on average.
| LW | RVTY | |
|---|---|---|
Market Cap | $6.81B | $16.98B |
Volume | 4,638,686 | 1,456,900 |
Sector | Consumer Staples | Health |
52-Week High | $66.57 | $157.36 |
52-Week Low | $38.48 | $82.26 |
Typical Hold Time | 66 Days | 12 Days |
Enterprise Value | $10.61B | $19.30B |
Dividend Yield | 3.07% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lamb Weston (LW) trades at $47.87, down 0.46% on the day, with a bullish technical signal supported by moving averages. The company shows consistent earnings beats in recent quarters, with Q3 2026 EPS of $0.75 exceeding expectations of $0.587. Revenue reached $6.45 billion in 2025, though net income margin declined to 3.85%. Analyst consensus price target stands at $53.71, representing 12% upside potential from current levels.
The stock presents a mixed outlook with strong technical momentum and earnings consistency offset by margin compression and elevated valuation at 27x P/E. Key risks include competitive pressures in the food industry and ongoing margin challenges. Institutional sentiment leans cautious with 63% hold ratings, suggesting limited near-term catalysts despite the technical bullish setup.
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
